Plus Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $1,390 | $1,059 | $1,412 | $1,456 |
Gross Profit | 1,304 | 878 | 1,180 | 1,224 |
EBITDA | 5,272 | -13,461 | -3,614 | -2,581 |
EBIT | 5,151 | -13,642 | -3,846 | -2,813 |
Net Income | 5,151 | -17,401 | -3,903 | -2,874 |
Net Change In Cash | 1,390 | 1,059 | 1,412 | 1,456 |
Free Cash Flow | -5,805 | -6,175 | -1,222 | -3,694 |
Cash | 2,233 | 9,867 | 76 | 1,223 |
Basic Shares | 209,154 | 14,567 | 5,896 | 7,856 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $5,824 | $4,913 | $224 | $0 |
Gross Profit | 4,972 | -4,777 | -488 | -66 |
EBITDA | -8,402 | -12,693 | -18,852 | -12,048 |
EBIT | -9,254 | -13,321 | -19,471 | -12,467 |
Net Income | -12,978 | -13,316 | -20,275 | -13,399 |
Net Change In Cash | 5,824 | 4,913 | 224 | 0 |
Free Cash Flow | -10,700 | -13,011 | -13,481 | -10,424 |
Cash | 76 | 8,554 | 18,120 | 18,400 |
Basic Shares | 7,701 | 3,140 | 1,750 | 805 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.006 |
2025-03-31 | -$0.56 |
2024-12-31 | -$0.49 |
2024-09-30 | -$0.37 |
